Form 4: ALX Oncology Executive Granted Stock Options

ALX Oncology Holdings Inc. SVP of Finance and CAO, Shelly Pinto, was granted 192,000 stock options at an exercise price of $1.48.

Summary

• Shelly Pinto, SVP, Finance and CAO of ALX Oncology Holdings Inc. (ALXO), was granted 192,000 stock options.
• The options have an exercise price of $1.48 per share.
• The transaction date for the option grant was January 26, 2026.
• The options vest in 48 equal monthly installments, commencing on February 26, 2026.
• The expiration date for these stock options is January 25, 2036.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as it reflects a routine executive compensation event, aligning management interests with shareholders and indicating executive retention. It is not highly impactful on its own but contributes to stable corporate governance.

Positives

• The grant of stock options aligns the interests of a key executive, Shelly Pinto, with those of shareholders, incentivizing long-term company performance.
• The transaction was conducted under a Rule 10b5-1(c) plan, indicating a pre-planned transaction designed to comply with insider trading regulations.

Future Outlook

This filing does not contain specific forward-looking statements or guidance regarding the company's future performance, but rather details an executive compensation event.

Industry Context

The grant of stock options to key executives is a standard practice in the biotechnology and pharmaceutical industries, serving as a common form of long-term incentive compensation to attract, retain, and motivate talent.

Comparison to Industry Standards

• The grant of stock options with a multi-year vesting schedule is a standard compensation mechanism in the biotech sector, comparable to practices at companies like Amgen, Gilead Sciences, or Biogen, which frequently use equity awards to align executive incentives with shareholder value creation.
• The use of a Rule 10b5-1 plan for this transaction is a best practice in corporate governance, demonstrating a commitment to transparency and compliance with insider trading regulations, consistent with industry leaders.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of stock options to a key executive aligns management's long-term financial interests with shareholder value creation, potentially leading to improved company performance.
• Employees: This compensation event may signal stability in executive leadership and a commitment to retaining key talent within the company.

Next Steps

• The stock options will begin vesting in 48 equal monthly installments starting February 26, 2026.

Key Dates

Keywords

ALX Oncology, ALXO, Stock Options, Executive Compensation, Form 4, Insider Transaction, Rule 10b5-1